secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005015
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028
-------------------------------------------------------------------------

- Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.
- Phase 1 interim data for SPY002 (TL1A) expected 2Q2025; SPY003 (IL-23) Phase 1 interim data in 2H2025.
- Phase 2 platform trial in UC launching mid-2025 with SPY001, SPY002, SPY003, and combinations; initial open-label data mid-2026.
- SPY002 expansion into rheumatoid arthritis; Phase 2 RA trial start mid-2025 with topline results in 2026.
- SPY001 Phase 1 data showed half-life >90 days, supporting quarterly to twice-annual subcutaneous dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/0001193125-25-005015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer